Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001051982 | SCV001216167 | uncertain significance | Hereditary spastic paraplegia 64 | 2019-03-21 | criteria provided, single submitter | clinical testing | This sequence change replaces valine with isoleucine at codon 224 of the ENTPD1 protein (p.Val224Ile). The valine residue is highly conserved and there is a small physicochemical difference between valine and isoleucine. This variant is present in population databases (rs372290136, ExAC 0.003%). This variant has not been reported in the literature in individuals with ENTPD1-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV003259060 | SCV003980613 | uncertain significance | Inborn genetic diseases | 2023-05-15 | criteria provided, single submitter | clinical testing | The c.706G>A (p.V236I) alteration is located in exon 6 (coding exon 6) of the ENTPD1 gene. This alteration results from a G to A substitution at nucleotide position 706, causing the valine (V) at amino acid position 236 to be replaced by an isoleucine (I). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |